No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers
Lynn Purkins(Ziarco (United Kingdom)), D. J. Nichols(Pfizer (United Kingdom)), Nolan Wood(Certara (United States)), Gary Layton(University of Geneva), Parviz Ghahramani(Pfizer (United Kingdom)), Diane Kleinermans(Erasmus Hospital)
Cited by 34
Related Papers
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
|Circulation|2011|375
Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension
|CHEST Journal|2011|257
STARTS-2
|Circulation|2014|212